Better Buy: Aurora Cannabis (TSX:ACB) vs Aphria Inc. (TSX:APHA)

As Aurora Cannabis (TSX:ACB)(NYSE:ACB) flexes its muscles and builds up inventory, Aphria Inc. (TSX:APHA)(NYSE:APHA) is becoming powerless to compete with the production champion.

| More on:
Financial technology concept.

Image source: Getty Images

The battle to win investors over in the cannabis space hasn’t weakened. Actually, it has become a war of attrition. Production king Aurora Cannabis (TSX:ACB)(NYSE:ACB) should be a shoe-in for market leadership. But can Aphria Inc. (TSX:APHA)(NYSE:APHA) slay the giant?

Cannabis producers are still in the limelight despite disappointing bottom line results. The top-tier, middle rung, and lower-tier industry players are on the level field right. All of them need to convert their exponential revenue growth into “real” profits. Investors are waiting grudgingly.

The pitch for Aurora Cannabis

The euphoria after enactment of the Cannabis Act last October quickly subsided because of supply shortages and the delayed opening of retail cannabis stores. But these problems somehow favour Aurora Cannabis. Being the largest cannabis producer, the company is expected to deliver during crunch time.

Aurora Cannabis reported sales of nine metric tons of marijuana during the fiscal third quarter. Production nearly doubled toward the end of the quarter as total harvest reached 15,590 kilograms. Overall, the Aurora Sky and Bradford facilities would yield an annual production output of 150,000 kilograms.

Based on their earnings report, net revenue rose 20% quarter-over-quarter amounting to $65 million. Recreation sales also grew by 37% versus the previous quarter.  Still, Aurora incurred $158-million loss in the quarter ended March 31, 2019. The company managed to cut the prior quarter’s losses by 33.6%

Analysts see Aurora Cannabis treading the right path to profitability. If Aurora Sky will continue to scale development at Aurora Sky, then gross margins could jump to 60% if not more. By this quarter’s end, total production would reach 25,000 kilograms.

In terms of stock performance, APHA is up over 72.12% year-to-date. With an estimated sales growth of +541.40% this year, analysts are forecasting a price appreciation of +41.4% or $16.50 at best. Aurora Cannabis is taking it one step at a time. Also, there is no impetus to rush into cannabis drinks. They know the right time will come.

Doomsday for Aphria?

It would be a pity to see Aphria losing steam. After recovering from a hostile takeover bid and short-selling allegations, the company was able to regain its bearings. APHA is up over 20.14% year-to-date and earlier this month, analysts are projecting as much as +175% stock price gain. The company has the makings of a giant slayer. However, another controversy is emerging.

Negative publicity has always put Aphria’s plans on hold. President Jakob Ripshtein has resigned and is heading for the exit door next month. This is a major blow indeed. Aphria can’t afford another issue that could frighten investors. A downtrend might develop from here.

With the fate of Aphria hanging in the balance again, the risks are higher. The loss of the topmost executive with extensive experience in the beverages industry dimmed their chances of penetrating the upcoming cannabis-infused beverage market.

Aurora Cannabis is a clear winner between the two weed stocks. The company will stand tall in the near-future, while Aphria might be crawling on its belly hoping for a white knight to rescue them.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »